Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$18.00M+525.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hadar Levy
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 129
- Beta
- 0.15
- Country
- IL
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 5.83
Financials
Revenue
$18.00M+525.7%Net Income
$2.20MEBITDA
$3.04MFree Cash Flow
$6.55MEPS (diluted)
$0.10Shares Outstanding (diluted)
22.22M+51.0%Operating Expenses
$11.45MCash & Debt
$63.18MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $52.23M | $7.63M | $0.40 |
| 2024 | $41.02M | $2.92M | $0.09 |
| 2023 | $31.79M | $-4.20M | $-0.13 |
| 2022 | $27.18M | $-13.35M | $-0.43 |
| 2021 | $29.66M | $-6.46M | $-0.21 |
| 2020 | $22.06M | $-5.38M | $-0.24 |
| 2019 | $23.10M | $-10.33M | $-0.50 |
| 2018 | $16.40M | $-6.48M | $-0.39 |
| 2017 | $11.14M | $-7.05M | $-0.48 |
| 2016 | $11.52M | $-2.40M | $-0.17 |
| 2015 | $6.80M | $-4.09M | $-0.28 |
| 2014 | $3.38M | $-6.54M | $-0.46 |
| 2013 | $1.19M | $-7.12M | $-0.55 |
| 2012 | $364.2K | $-5.92M | $-0.49 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.59
- Implied price
- $14.11
- Return from $10.11
- 6.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $7.01 — -30.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| -2.0% | -10.6% | -6.5% | -3.0% | 0.0% | 2.7% |
| 3.0% | -6.0% | -1.7% | 1.9% | 5.1% | 8.0% |
| 8.0% | -1.4% | 3.1% | 6.9% | 10.2% | 13.2% |
| 13.0% | 3.1% | 7.8% | 11.8% | 15.3% | 18.5% |
| 18.0% | 7.7% | 12.6% | 16.8% | 20.4% | 23.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
45-35.71%Social Signal Score
Mentions (13)
- Newsfool.com·11d ago·Neutral
BrainsWay: 3 Key Takeaways for Long-Term Investors BrainsWay shipped 130 Deep TMS systems in the third quarter. U.S. insurance reimbursement for SWIFT reached 70 million covered lives.
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
What Brainsway (BWAY) Said on Its Q3 Earnings Call Brainsway NASDAQ: BWAY reported 34% revenue growth and a more than doubling of operating income in the third quarter of 2026, as shipments of its Deep TMS systems increased and reimbursement coverage expanded for its accelerated treatment protocol.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
BrainsWay Ltd. (BWAY) Q3 2026 Earnings Call Transcript BrainsWay Ltd. (BWAY) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…to Report Third Quarter 2026 Financial Results on November 10, 2026 BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 10, 2026. The Comp…
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
…e Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS™ in the treatment of patients suffering from obsessive compulsive disorder (OCD).
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments
View source ↗ - Newsglobenewswire.com·40d ago·Negative
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™ Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
View source ↗ - Newszacks.com·87d ago·Positive
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High? The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newszacks.com·97d ago·Positive
Brainsway (BWAY) Upgraded to Buy: Here's Why Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsmarketbeat.com·101d ago·Neutral
Brainsway Q2 Earnings Call Highlights Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·102d ago·Negative
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
View source ↗
Earnings
Wed, Mar 10(in 4 months)
Consensus estimate $0.13 per share
Typical surprise +32.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$0.10 vs $0.12miss
- Wed, Aug 12$0.14 vs $0.10beat
- Wed, May 13$0.12 vs $0.05beat
- Wed, Mar 11$0.14 vs $0.06beat
- Tue, Nov 11$0.04 vs $0.05miss
- Wed, Aug 13$0.05 vs $0.04beat
Estimates and results for BWAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BWAY officers and directors.
- Bought
- —
- Sold
- —
0 trades
3 trades
- Moiseyev Giladsold
- Mitrany Rayten Michal Etysold
- Mitrany Rayten Michal Etysold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BWAY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
